

Apremilast-d₅

| | | | |
|---------------------------|--|-------|----------|
| Cat. No.: | HY-12085S | | |
| CAS No.: | 1258597-47-5 | | |
| Molecular Formula: | C ₂₂ H ₁₉ D ₅ N ₂ O ₇ S | | |
| Molecular Weight: | 465.53 | | |
| Target: | Phosphodiesterase (PDE); Apoptosis; TNF Receptor | | |
| Pathway: | Metabolic Enzyme/Protease; Apoptosis | | |
| Storage: | Powder | -20°C | 3 years |
| | | 4°C | 2 years |
| | In solvent | -80°C | 6 months |
| | | -20°C | 1 month |



SOLVENT & SOLUBILITY

In Vitro

DMSO : 100 mg/mL (214.81 mM; Need ultrasonic)

| Concentration | Solvent | Mass | | |
|---------------------------|---------|-----------|------------|------------|
| | | 1 mg | 5 mg | 10 mg |
| Preparing Stock Solutions | 1 mM | 2.1481 mL | 10.7404 mL | 21.4809 mL |
| | 5 mM | 0.4296 mL | 2.1481 mL | 4.2962 mL |
| | 10 mM | 0.2148 mL | 1.0740 mL | 2.1481 mL |

Please refer to the solubility information to select the appropriate solvent.

BIOLOGICAL ACTIVITY

Description

Apremilast-d₅ is a deuterium labeled Apremilast. Apremilast is an orally available inhibitor of type-4 cyclic nucleotide phosphodiesterase (PDE-4) with an IC₅₀ of 74 nM. Apremilast inhibits TNF-α release by lipopolysaccharide (LPS) with an IC₅₀ of 104 nM[1].

IC₅₀ & Target

PDE4

REFERENCES

[1]. Perez-Aso M, et al. Apremilast, a novel phosphodiesterase 4 (PDE4) inhibitor, regulates inflammation through multiple cAMP downstream effectors. *Arthritis Res Ther.* 2015 Sep 15;17:249.

Caution: Product has not been fully validated for medical applications. For research use only.

Tel: 609-228-6898

Fax: 609-228-5909

E-mail: tech@MedChemExpress.com

Address: 1 Deer Park Dr, Suite Q, Monmouth Junction, NJ 08852, USA